SK bioscience Statistics

Total Valuation

SK bioscience has a market cap or net worth of KRW 4.02 trillion. The enterprise value is 3.47 trillion.

Market Cap	4.02T
Enterprise Value	3.47T

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

SK bioscience has 78.37 million shares outstanding. The number of shares has increased by 0.72% in one year.

Current Share Class	78.37M
Shares Outstanding	78.37M
Shares Change (YoY)	+0.72%
Shares Change (QoQ)	+0.26%
Owned by Insiders (%)	0.11%
Owned by Institutions (%)	3.54%
Float	25.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.06
PB Ratio	1.97
P/TBV Ratio	2.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-72.90
EV / Sales	8.68
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-20.97

Financial Position

The company has a current ratio of 4.46, with a Debt / Equity ratio of 0.20.

Current Ratio	4.46
Quick Ratio	3.78
Debt / Equity	0.20
Debt / EBITDA	n/a
Debt / FCF	-2.44
Interest Coverage	-21.48

Financial Efficiency

Return on equity (ROE) is -2.17% and return on invested capital (ROIC) is -3.70%.

Return on Equity (ROE)	-2.17%
Return on Assets (ROA)	-3.25%
Return on Invested Capital (ROIC)	-3.70%
Return on Capital Employed (ROCE)	-4.91%
Revenue Per Employee	406.33M
Profits Per Employee	-48.40M
Employee Count	984
Asset Turnover	0.17
Inventory Turnover	2.19

Taxes

Income Tax	-42.63B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1.38% in the last 52 weeks. The beta is 1.22, so SK bioscience's price volatility has been higher than the market average.

Beta (5Y)	1.22
52-Week Price Change	+1.38%
50-Day Moving Average	41,796.00
200-Day Moving Average	47,880.00
Relative Strength Index (RSI)	76.44
Average Volume (20 Days)	203,528

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SK bioscience had revenue of KRW 399.83 billion and -47.63 billion in losses. Loss per share was -613.92.

Revenue	399.83B
Gross Profit	50.75B
Operating Income	-125.46B
Pretax Income	-83.10B
Net Income	-47.63B
EBITDA	-64.19B
EBIT	-125.46B
Loss Per Share	-613.92

Full Income Statement

Balance Sheet

The company has 1.18 trillion in cash and 403.18 billion in debt, giving a net cash position of 780.38 billion or 9,957.77 per share.

Cash & Cash Equivalents	1.18T
Total Debt	403.18B
Net Cash	780.38B
Net Cash Per Share	9,957.77
Equity (Book Value)	2.04T
Book Value Per Share	23,081.62
Working Capital	1.20T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -33.71 billion and capital expenditures -131.84 billion, giving a free cash flow of -165.55 billion.

Operating Cash Flow	-33.71B
Capital Expenditures	-131.84B
Free Cash Flow	-165.55B
FCF Per Share	-2,112.40

Full Cash Flow Statement

Margins

Gross margin is 12.69%, with operating and profit margins of -31.38% and -11.91%.

Gross Margin	12.69%
Operating Margin	-31.38%
Pretax Margin	-20.78%
Profit Margin	-11.91%
EBITDA Margin	-16.05%
EBIT Margin	-31.38%
FCF Margin	n/a

Dividends & Yields

SK bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.72%
Shareholder Yield	n/a
Earnings Yield	-1.18%
FCF Yield	-4.12%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SK bioscience has an Altman Z-Score of 3.55 and a Piotroski F-Score of 1.

Altman Z-Score	3.55
Piotroski F-Score	1